In a new paper, researchers sought to describe how much the European Union is overspending on neovascular age-related macular degeneration treatment by relying on ranibizumab and aflibercept rather than bevacizumab in ophthalmology.
Bevacizumab represents an effective and relatively inexpensive anti—vascular endothelial growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (AMD), but because it is not approved for this indication, many physicians are discouraged from using bevacizumab to treat AMD. Even the United Kingdom’s National Institute for Health and Care Excellence (NICE) recommends using the more expensive anti-VEGF treatments ranibizumab or aflibercept to treat this disease.
In a new paper in PLOS One, researchers sought to describe how much the European Union is overspending on AMD treatment by relying on ranibizumab and aflibercept rather than bevacizumab in ophthalmology.
The researchers developed a patient-level decision analytic model to evaluate effectiveness, quality of life, and costs to compare ranibizumab used as needed and aflibercept administered bimonthly with bevacizumab used as needed. The model estimated the mean costs and benefits for a hypothetical group over a 1-year time horizon. To determine effectiveness of each drug, the researchers used a systematic review and meta-analysis of the literature. Costs were calculated from a societal perspective, including direct costs (including drug costs, medical visits, and examinations) and indirect costs (including the costs of low vision aids and nonmedical costs). They used a willingness-to-pay (WTP) threshold of €80,000 (approximately $93,325) per quality-adjusted life year (QALY). Overspending was defined as the amount of extra money paid for health care that cannot be justified by the WTP threshold of €80,000.
The researchers found:
They also compared aflibercept with bevacizumab to demonstrate what would be needed for it to be a justifiable alternative to bevacizumab, and found that aflibercept should be reduced from €943 (approximately $1100) to €533 (approximately $622) per injection. If aflibercept were to meet the WTP threshold practiced by NICE, it would have to be discounted to €447 (approximately $522) per injection. Alternatively, at its current price, aflibercept should provide at least an additional 0.041 QALYs per patient versus bevacizumab.
The United Kingdom alone, write the authors, is overspending by €52.5 million (approximately $60.6 million) annually. Europe as a whole could save €335 million (approximately $386 million) yearly by treating 80% of people with AMD with bevacizumab rather than aflibercept.
“The awareness of the importance of cost-effectiveness to keep health care sustainable is growing and new drugs should be critically appraised on their added value,” write the authors. “In the case of neovascular AMD treatment there is no question; bevacizumab is the most cost-effective anti-VEGF treatment for AMD.”
Reference
van Asten F, Michels CTJ, Hyong CB, et al. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration—a cost-effectiveness analysis from a societal perspective. [Published online May 17, 2018.] PLoS One. doi: 10.1371/journal.pone.0197670.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.